DULOXETINE (duloxetine) by Almatica Pharma is antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the cns. First approved in 2026.
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant approved as a delayed-release capsule. It is indicated for depression, anxiety, chronic pain conditions, and other CNS disorders through potentiation of serotonergic and noradrenergic activity in the central nervous system.
Early-stage launch offering growth potential; Almatica Pharma will be building commercial infrastructure and team capacity.
antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer
A Study Of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta Under Fed Conditions
A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta
A Study of Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents With Depressive Disorder
Worked on DULOXETINE at Almatica Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moDuloxetine launch at Almatica Pharma represents entry-level to mid-career opportunity in a competitive CNS market; roles will focus on formulary access, prescriber education, and market penetration. Long patent exclusivity (19+ years) provides career stability and potential for advancement within a growing franchise.